

# Contents

<b>Foreword</b> .....	vii
<b>List of participants</b> .....	viii
<b>Workshop report</b> .....	1
<b>Surrogate end-point biomarkers in chemopreventive drug development</b>	
<i>G.J. Kelloff, C.C. Sigman, E.T. Hawk, K.M. Johnson, J.A. Crowell and K.Z. Guyton</i>	13
<b>Biomarkers and surrogacy: relevance to chemoprevention</b>	
<i>T.W. Kensler, N.E. Davidson, J.D. Groopman and A. Munoz</i>	27
<b>Development of difluoromethylornithine and Bowman-Birk inhibitor as chemopreventive agents by assessment of relevant biomarker modulation: some lessons learned</b>	
<i>F.L. Meyskens, Jr.</i>	49
<b>Selection and validation of biomarkers for chemoprevention: the contribution of epidemiology</b>	
<i>P. Vineis and F. Veglia</i>	57
<b>Skin cancer</b>	
<b>Ultraviolet radiation-induced photoproducts in human skin DNA as biomarkers of damage and its repair</b>	
<i>K. Hemminki, G. Xu and F. Le Curieux</i>	69
<b>Intermediate-effect biomarks in prevention of skin cancer</b>	
<i>J.-F. Doré, R. Pedeux, M. Boniol, M.-C. Chignol and P. Autier</i>	81
<b>Genetically determined susceptibility markers in skin cancer and their application to chemoprevention</b>	
<i>H. Hahn</i>	93
<b>Colorectal cancer</b>	
<b>Biomarkers in colorectal cancer</b>	
<i>R.W. Owen</i>	101
<b>Intermediate effect markers for colorectal cancer</b>	
<i>J.A. Baron</i>	113
<b>Susceptibility markers in colorectal cancer</b>	
<i>J. Burn, P.D. Chapman, D.T. Bishop, S. Smalley, I. Mickleburgh, S. West and J.C. Mathers</i>	131

**Breast cancer**

**Endogenous hormone metabolism as an exposure marker in breast cancer chemoprevention studies**

*R. Kaaks* ..... 149

**Mammographic density as a marker of susceptibility to breast cancer: a hypothesis**

*N.F. Boyd, G.A. Lockwood, L.J. Martin, J.W. Byng, M.J. Yaffe and D.L. Tritchler* ..... 163

**Intermediate histological effect markers for breast cancer**

*A.B. Miller and A.M. Borges* ..... 171

**Inherited genetic susceptibility to breast cancer**

*J. Chang-Claude* ..... 177

**Prostate cancer**

**High-grade prostatic intraepithelial neoplasia as an exposure biomarker for prostate cancer chemoprevention research**

*J.R. Marshall* ..... 191

**Intermediate biomarkers for chemoprevention of prostate cancer**

*T.H. van der Kwast* ..... 199

**The role of molecular genetics in chemoprevention studies of prostate cancer**

*R.K. Ross* ..... 207

**Liver cancer**

**Exposure biomarkers in chemoprevention studies of liver cancer**

*C.P. Wild and P.C. Turner* ..... 215

**Significance of hepatic preneoplasia for cancer chemoprevention**

*P. Bannasch, D. Nehrbass and A. Kopp-Schneider* ..... 223

**Hepatocellular carcinoma: susceptibility markers**

*H.E. Blum* ..... 241

**Lung and oral cavity cancer**

**Carcinogen biomarkers for lung or oral cancer chemoprevention trials**

*S.S. Hecht* ..... 245

**Lung cancer: chemoprevention and intermediate effect markers**

*M.S. Tockman* ..... 257

**Metabolic polymorphisms as susceptibility markers for lung and oral cavity cancer**

*U. Nair and H. Bartsch* ..... 271